Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akso Health (AHG) Cash & Equivalents (2017 - 2025)

Akso Health (AHG) has disclosed Cash & Equivalents for 8 consecutive years, with $176.2 million as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Cash & Equivalents rose 106.91% year-over-year to $176.2 million, compared with a TTM value of $176.2 million through Mar 2025, up 106.91%, and an annual FY2025 reading of $176.2 million, up 106.91% over the prior year.
  • Cash & Equivalents was $176.2 million for Q1 2025 at Akso Health, up from $85.2 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $176.2 million in Q1 2025 and bottomed at $9.2 million in Q1 2023.
  • Average Cash & Equivalents over 5 years is $61.5 million, with a median of $21.9 million recorded in 2022.
  • The sharpest move saw Cash & Equivalents crashed 58.07% in 2023, then surged 826.54% in 2024.
  • Year by year, Cash & Equivalents stood at $15.1 million in 2021, then skyrocketed by 44.93% to $21.9 million in 2022, then plummeted by 58.07% to $9.2 million in 2023, then soared by 826.54% to $85.2 million in 2024, then skyrocketed by 106.91% to $176.2 million in 2025.
  • Business Quant data shows Cash & Equivalents for AHG at $176.2 million in Q1 2025, $85.2 million in Q1 2024, and $9.2 million in Q1 2023.